Apogee Therapeutics, Inc. (APGE) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Apogee Therapeutics, Inc.
Address
221 Crescent Street
Waltham, MA 02453
United States of America (the)
Phone
650-394-5230
Sector
Healthcare
Industry
Biotechnology
Employees
196
First IPO Date
July 14, 2023
Key Executives
| Name | Title | Pay | Year Born |
| Michael Thomas Henderson | Chief Executive Officer & Director | 1.29M | 1990 |
| Jane Pritchett V. Henderson | Chief Financial Officer | 855,900 | 1966 |
| Carl Linden Dambkowski | Chief Medical Officer | 855,900 | 1985 |
| Rebecca Dabora | Chief Development Officer | 0 | 1960 |
| Noel Kurdi | Vice President of Investor Relations | 0 | N/A |
| Wendy Aspden-Curran | Senior Vice President of Clinical Operations | 0 | N/A |
| Mehrak Kiankarimi | Senior Vice President of Program & Portfolio | 0 | N/A |
| Dan Mulreany | Chief Business Officer | 0 | N/A |
| Monica Forbes | Senior Vice President of Finance | 0 | 1976 |
| Matthew Batters | Chief Legal Officer & Corporate Secretary | 0 | 1976 |
| Emily Cox | SVP & Head of People | 0 | N/A |
| Drew Badger | Senior Vice President and Head of Regulatory Affairs & Toxicology | 0 | N/A |
Description
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
